The University of Chicago Header Logo

Connection

Anthony T. Reder to Multiple Sclerosis

Back to Details
This is a "connection" page, showing publications Anthony T. Reder has written about Multiple Sclerosis.
Anthony T. Reder
Connection Strength
17.812
Multiple Sclerosis
  1. Alternative Splicing of RNA Is Excessive in Multiple Sclerosis and Not Linked to Gene Expression Levels: Dysregulation Is Corrected by IFN-ß. J Interferon Cytokine Res. 2024 08; 44(8):355-371.
    View in: PubMed
    Score: 0.787
  2. Novel biomarkers and interferon signature in secondary progressive multiple sclerosis. J Neuroimmunol. 2024 04 15; 389:578328.
    View in: PubMed
    Score: 0.779
  3. Clostridium epsilon toxin is excessive in multiple sclerosis and provokes multifocal lesions in mouse models. J Clin Invest. 2023 05 01; 133(9).
    View in: PubMed
    Score: 0.734
  4. Prolonged Interferon-Stimulated Gene and Protein Signatures in Multiple Sclerosis Induced by PEGylated IFN-ß-1a Compared to Non-PEGylated IFN-ß-1a. J Interferon Cytokine Res. 2023 03; 43(3):108-120.
    View in: PubMed
    Score: 0.726
  5. Increased Percentage of CD8+CD28- Regulatory T Cells With Fingolimod Therapy in Multiple Sclerosis. Neurol Neuroimmunol Neuroinflamm. 2023 03; 10(2).
    View in: PubMed
    Score: 0.716
  6. T cell responses to COVID-19 infection and vaccination in patients with multiple sclerosis receiving disease-modifying therapy. Mult Scler. 2023 05; 29(6):648-656.
    View in: PubMed
    Score: 0.713
  7. Medications for Multiple Sclerosis and Risk of Malignancy: What Next? Neurotherapeutics. 2021 07; 18(3):1650-1653.
    View in: PubMed
    Score: 0.653
  8. Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis. Mult Scler Relat Disord. 2021 Jun; 51:102935.
    View in: PubMed
    Score: 0.637
  9. Anti-CD20 therapy corrects a CD8 regulatory T cell deficit in multiple sclerosis. Mult Scler. 2021 12; 27(14):2170-2179.
    View in: PubMed
    Score: 0.636
  10. COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies. CNS Drugs. 2021 03; 35(3):317-330.
    View in: PubMed
    Score: 0.634
  11. Thoracic flexion provokes circumferential dysesthesia: A symptom of thoracic cord lesions in MS. Mult Scler. 2021 06; 27(7):1008-1013.
    View in: PubMed
    Score: 0.602
  12. Interferon-ß corrects massive gene dysregulation in multiple sclerosis: Short-term and long-term effects on immune regulation and neuroprotection. EBioMedicine. 2019 Nov; 49:269-283.
    View in: PubMed
    Score: 0.575
  13. Vitamin D enhances responses to interferon-ß in MS. Neurol Neuroimmunol Neuroinflamm. 2019 11; 6(6):e622.
    View in: PubMed
    Score: 0.573
  14. Patient Preferences for Injectable Treatments for Multiple Sclerosis in the United States: A Discrete-Choice Experiment. Patient. 2016 Apr; 9(2):171-80.
    View in: PubMed
    Score: 0.450
  15. How type I interferons work in multiple sclerosis and other diseases: some unexpected mechanisms. J Interferon Cytokine Res. 2014 Aug; 34(8):589-99.
    View in: PubMed
    Score: 0.400
  16. The effects of long-term interferon-beta-1b treatment on cognitive functioning in multiple sclerosis: a 16-year longitudinal study. Mult Scler. 2013 Nov; 19(13):1765-72.
    View in: PubMed
    Score: 0.368
  17. Response to GS Gronseth and E Ashman. Mult Scler. 2012 Nov; 18(11):1661-2; author reply 1663-4.
    View in: PubMed
    Score: 0.355
  18. Inhibition of interferon-beta responses in multiple sclerosis immune cells associated with high-dose statins. Arch Neurol. 2012 Oct; 69(10):1303-9.
    View in: PubMed
    Score: 0.353
  19. Evidence-based medicine: promise and pitfalls. Mult Scler. 2012 Jul; 18(7):947-8.
    View in: PubMed
    Score: 0.347
  20. MxA: a biomarker for predicting multiple sclerosis disease activity. Neurology. 2010 Oct 05; 75(14):1222-3.
    View in: PubMed
    Score: 0.307
  21. Multiple sclerosis. Part I: neuro-ophthalmic manifestations. Curr Opin Ophthalmol. 2009 Nov; 20(6):467-75.
    View in: PubMed
    Score: 0.288
  22. 4-Aminopyridine toxicity mimics autoimmune-mediated limbic encephalitis. Neurology. 2009 Mar 24; 72(12):1100-1.
    View in: PubMed
    Score: 0.276
  23. Therapeutic role of beta-interferons in multiple sclerosis. Pharmacol Ther. 2006 Apr; 110(1):35-56.
    View in: PubMed
    Score: 0.218
  24. Anti-myelin oligodendrocyte glycoprotein antibodies in multiple sclerosis. Neurology. 2004 Jun 08; 62(11):1922-3.
    View in: PubMed
    Score: 0.198
  25. Abnormal levels of interferon-gamma receptors in active multiple sclerosis are normalized by IFN-beta therapy: implications for control of apoptosis. Front Biosci. 2004 May 01; 9:1547-55.
    View in: PubMed
    Score: 0.197
  26. Demographics and baseline disease characteristics of Black and Hispanic patients with multiple sclerosis in the open-label, single-arm, multicenter, phase IV CHIMES trial. Mult Scler Relat Disord. 2023 Aug; 76:104794.
    View in: PubMed
    Score: 0.185
  27. Understanding humoral immunity and multiple sclerosis severity in Black, and Latinx patients. Front Immunol. 2023; 14:1172993.
    View in: PubMed
    Score: 0.184
  28. Psychometric evaluation of the Chicago Multiscale Depression Inventory in multiple sclerosis patients. Mult Scler. 2003 Mar; 9(2):160-70.
    View in: PubMed
    Score: 0.181
  29. Effectiveness of ocrelizumab on clinical and MRI outcome measures in multiple sclerosis across black and white cohorts: A single-center retrospective study. Mult Scler Relat Disord. 2023 Mar; 71:104523.
    View in: PubMed
    Score: 0.180
  30. Low expression of interferon-stimulated genes in active multiple sclerosis is linked to subnormal phosphorylation of STAT1. J Neuroimmunol. 2002 Aug; 129(1-2):205-15.
    View in: PubMed
    Score: 0.174
  31. Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial. Mult Scler. 2022 04; 28(5):790-800.
    View in: PubMed
    Score: 0.163
  32. Interferons and Multiple Sclerosis: Lessons from 25 Years of Clinical and Real-World Experience with Intramuscular Interferon Beta-1a (Avonex). CNS Drugs. 2021 07; 35(7):743-767.
    View in: PubMed
    Score: 0.162
  33. Disability improvement as a clinically relevant outcome in clinical trials of relapsing forms of multiple sclerosis. Mult Scler. 2021 12; 27(14):2219-2231.
    View in: PubMed
    Score: 0.159
  34. Injecting rationale into interferon-beta therapy. Neurology. 2000 Jun 13; 54(11):2034-5.
    View in: PubMed
    Score: 0.150
  35. Gray matter atrophy in multiple sclerosis despite clinical and lesion stability during natalizumab treatment. PLoS One. 2018; 13(12):e0209326.
    View in: PubMed
    Score: 0.136
  36. Monocyte activation in multiple sclerosis. Mult Scler. 1998 Jun; 4(3):162-8.
    View in: PubMed
    Score: 0.131
  37. Effects of an anti-IL-10 monoclonal antibody on rIFNbeta-1b-mediated immune modulation. Relevance to multiple sclerosis. J Neuroimmunol. 1998 Jan; 81(1-2):109-15.
    View in: PubMed
    Score: 0.127
  38. Interferon beta-1b effects on cytokine mRNA in peripheral mononuclear cells in multiple sclerosis. Mult Scler. 1996 Apr; 1(5):262-9.
    View in: PubMed
    Score: 0.112
  39. Relapses in multiple sclerosis: Relationship to disability. Mult Scler Relat Disord. 2016 Mar; 6:10-20.
    View in: PubMed
    Score: 0.108
  40. Interferon effects on interleukin-10 secretion. Mononuclear cell response to interleukin-10 is normal in multiple sclerosis patients. J Neuroimmunol. 1995 Aug; 61(1):27-34.
    View in: PubMed
    Score: 0.107
  41. Trigeminal neuralgia in multiple sclerosis relieved by a prostaglandin E analogue. Neurology. 1995 Jun; 45(6):1097-100.
    View in: PubMed
    Score: 0.106
  42. Induction of a unique isoform of the NCOA7 oxidation resistance gene by interferon ß-1b. J Interferon Cytokine Res. 2015 Mar; 35(3):186-99.
    View in: PubMed
    Score: 0.102
  43. IFN-gamma, IFN-beta, and PGE1 affect monokine secretion: relevance to monocyte activation in multiple sclerosis. Cell Immunol. 1994 Sep; 157(2):428-38.
    View in: PubMed
    Score: 0.101
  44. Adrenal size is increased in multiple sclerosis. Arch Neurol. 1994 Feb; 51(2):151-4.
    View in: PubMed
    Score: 0.097
  45. Genetic variation near IRF8 is associated with serologic and cytokine profiles in systemic lupus erythematosus and multiple sclerosis. Genes Immun. 2013 Dec; 14(8):471-8.
    View in: PubMed
    Score: 0.094
  46. Serum prolactin levels in active multiple sclerosis and during cyclosporin treatment. J Neurol Sci. 1993 Jul; 117(1-2):192-6.
    View in: PubMed
    Score: 0.093
  47. Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosis. Ophthalmology. 2013 Jul; 120(7):1432-9.
    View in: PubMed
    Score: 0.091
  48. Cystoid macular edema associated with fingolimod use for multiple sclerosis. JAMA Ophthalmol. 2013 Jan; 131(1):103-7.
    View in: PubMed
    Score: 0.090
  49. Brief International Cognitive Assessment for MS (BICAMS): international standards for validation. BMC Neurol. 2012 Jul 16; 12:55.
    View in: PubMed
    Score: 0.087
  50. Interferon-beta-1b-induced short- and long-term signatures of treatment activity in multiple sclerosis. Pharmacogenomics J. 2013 Oct; 13(5):443-51.
    View in: PubMed
    Score: 0.086
  51. Interferon-beta treatment does not elevate cortisol in multiple sclerosis. J Interferon Res. 1992 Jun; 12(3):195-8.
    View in: PubMed
    Score: 0.086
  52. Recommendations for a Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS). Mult Scler. 2012 Jun; 18(6):891-8.
    View in: PubMed
    Score: 0.084
  53. Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon ß-1b trial in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2012 Mar; 83(3):282-7.
    View in: PubMed
    Score: 0.084
  54. Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. Ann Neurol. 2011 Dec; 70(6):897-912.
    View in: PubMed
    Score: 0.083
  55. Establishing long-term efficacy in chronic disease: use of recursive partitioning and propensity score adjustment to estimate outcome in MS. PLoS One. 2011; 6(11):e22444.
    View in: PubMed
    Score: 0.083
  56. The function of the CD2 protein is abnormal in multiple sclerosis. J Autoimmun. 1991 Jun; 4(3):479-91.
    View in: PubMed
    Score: 0.080
  57. Soluble CD8 levels in the CSF and serum of patients with multiple sclerosis. Neurology. 1991 Jun; 41(6):851-4.
    View in: PubMed
    Score: 0.080
  58. Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis. J Neuroimmunol. 1991 Apr; 32(1):67-74.
    View in: PubMed
    Score: 0.079
  59. Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol. 2010 Jul; 9(7):740-50.
    View in: PubMed
    Score: 0.075
  60. Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial. J Neurol Neurosurg Psychiatry. 2010 Aug; 81(8):907-12.
    View in: PubMed
    Score: 0.075
  61. Recognizing and treating suboptimally controlled multiple sclerosis: steps toward regaining command. Curr Med Res Opin. 2009 Oct; 25(10):2459-70.
    View in: PubMed
    Score: 0.072
  62. Neuroendocrine regulation and the immune response in MS. Res Immunol. 1989 Feb; 140(2):239-45; discussion 245-8.
    View in: PubMed
    Score: 0.068
  63. Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Neurology. 2008 Jul 08; 71(2):136-44.
    View in: PubMed
    Score: 0.066
  64. Activated suppressor cell function in multiple sclerosis--clinical correlations. J Neuroimmunol. 1988 Mar; 17(4):323-30.
    View in: PubMed
    Score: 0.064
  65. Blood lymphocyte beta-adrenergic receptors in multiple sclerosis. Ann N Y Acad Sci. 1988; 540:585-8.
    View in: PubMed
    Score: 0.063
  66. Immunoregulation in rapidly progressive multiple sclerosis. Ann N Y Acad Sci. 1988; 540:4-12.
    View in: PubMed
    Score: 0.063
  67. Dexamethasone suppression test abnormalities in multiple sclerosis: relation to ACTH therapy. Neurology. 1987 May; 37(5):849-53.
    View in: PubMed
    Score: 0.061
  68. Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2007 Mar 27; 68(13):977-84.
    View in: PubMed
    Score: 0.060
  69. Molecular analysis of the CD8 gene in multiple sclerosis. J Neuroimmunol. 1987 Mar; 14(2):183-7.
    View in: PubMed
    Score: 0.060
  70. Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis. Neurology. 2006 Feb 28; 66(4):472-6.
    View in: PubMed
    Score: 0.056
  71. Low T8 antigen density on lymphocytes in active multiple sclerosis. Ann Neurol. 1984 Aug; 16(2):242-9.
    View in: PubMed
    Score: 0.050
  72. T regulator cell surface antigens in multiple sclerosis. Ann N Y Acad Sci. 1984; 436:247-53.
    View in: PubMed
    Score: 0.048
  73. Immunoregulation in multiple sclerosis. Ann N Y Acad Sci. 1984; 436:133-9.
    View in: PubMed
    Score: 0.048
  74. Clinical spectrum of multiple sclerosis. Neurol Clin. 1983 Aug; 1(3):573-99.
    View in: PubMed
    Score: 0.047
  75. B-cell differentiation in multiple sclerosis and the effect of intravenous ACTH. Neurology. 1983 Apr; 33(4):442-6.
    View in: PubMed
    Score: 0.046
  76. Increased CD80(+) B cells in active multiple sclerosis and reversal by interferon beta-1b therapy. J Clin Invest. 1997 Jun 01; 99(11):2664-71.
    View in: PubMed
    Score: 0.030
  77. Improved delayed visual reproduction test performance in multiple sclerosis patients receiving interferon beta-1b. Neurology. 1996 Dec; 47(6):1463-8.
    View in: PubMed
    Score: 0.029
  78. The mast cells of the multiple sclerosis brain. J Neuroimmunol. 1996 Nov; 70(2):131-8.
    View in: PubMed
    Score: 0.029
  79. Validation of the functional assessment of multiple sclerosis quality of life instrument. Neurology. 1996 Jul; 47(1):129-39.
    View in: PubMed
    Score: 0.029
  80. Mechanisms of action of interferon-beta in multiple sclerosis. Springer Semin Immunopathol. 1996; 18(1):125-48.
    View in: PubMed
    Score: 0.028
  81. Urinary myelin basic protein-like material as a correlate of the progression of multiple sclerosis. Ann Neurol. 1995 Oct; 38(4):625-32.
    View in: PubMed
    Score: 0.027
  82. Increased high affinity beta-adrenergic receptor densities and cyclic AMP responses of CD8 cells in multiple sclerosis. J Neuroimmunol. 1993 Mar; 43(1-2):1-7.
    View in: PubMed
    Score: 0.023
  83. T cell lymphokine-induced secretion of cytokines by monocytes from patients with multiple sclerosis. Cell Immunol. 1993 Jan; 146(1):96-106.
    View in: PubMed
    Score: 0.022
  84. Increased muscarinic cholinergic receptor density on CD4+ lymphocytes in progressive multiple sclerosis. J Neuroimmunol. 1992 Feb; 36(2-3):171-7.
    View in: PubMed
    Score: 0.021
  85. Three-dimensional human pattern visual evoked potentials. II. Multiple sclerosis patients. Electroencephalogr Clin Neurophysiol. 1991 Sep-Oct; 80(5):339-46.
    View in: PubMed
    Score: 0.020
  86. Increased lymphocyte beta-adrenergic receptor density in progressive multiple sclerosis is specific for the CD8+, CD28- suppressor cell. Ann Neurol. 1991 Jul; 30(1):42-7.
    View in: PubMed
    Score: 0.020
  87. Internal capsule plaque and tonic spasms in multiple sclerosis. Arch Neurol. 1991 Apr; 48(4):427-9.
    View in: PubMed
    Score: 0.020
  88. Sympathetic skin responses are decreased and lymphocyte beta-adrenergic receptors are increased in progressive multiple sclerosis. Ann Neurol. 1990 Apr; 27(4):366-72.
    View in: PubMed
    Score: 0.019
  89. ACTH production by human mononuclear cells. Ann N Y Acad Sci. 1988; 540:589-91.
    View in: PubMed
    Score: 0.016
  90. Comparison of T8+ cell-mediated suppressor and cytotoxic functions in multiple sclerosis. J Neuroimmunol. 1986 Sep; 12(3):215-24.
    View in: PubMed
    Score: 0.014
  91. Suppressor and cytolytic cell function in multiple sclerosis. Effects of cyclosporine A and interleukin 2. J Clin Invest. 1986 Aug; 78(2):582-6.
    View in: PubMed
    Score: 0.014
  92. Activated suppressor cell dysfunction in progressive multiple sclerosis. J Immunol. 1986 Jul 01; 137(1):137-41.
    View in: PubMed
    Score: 0.014
  93. Multiple sclerosis: relation of in vitro IgG secretion to T suppressor cell number and function. Neurology. 1984 Sep; 34(9):1155-60.
    View in: PubMed
    Score: 0.013
  94. Analysis of T regulator cell surface markers and functional properties in multiple sclerosis. J Neuroimmunol. 1984 Apr; 6(2):93-103.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.